At the last check on Thursday, CNS Pharmaceuticals Inc.’s (NASDAQ:CNSP) stock was up $0.04, moving up 14.29 percent to $0.32. The average number of shares traded per day over the past five days has been 1,890,186 shares. 5 times new highs have been achieved over the past 5 days, with a $0.0543 gain in that time frame. In the last twenty days, the average volume was 812,351, while in the previous 50 days, it was 668,829.
Since last month, CNSP stock rose 1.45%. Shares of the company fell to $0.2505 on 05/24/22, the lowest level in the past month. A 52-week high of $2.68 was reached on 01/05/22 after having rallying from a 52-week low of $0.25. Since the beginning of this year, CNSP’s stock price has dropped by -60.14% or -$0.3754, and marked a new high 2 times. However, the stock has declined by -88.06% since its 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
CNS Pharmaceuticals Inc. (CNSP) last reported insider trading activity 199 days ago on Dec 06. Downs Christopher, the Chief Financial Officer of the company, purchased of 5,000 shares for $0.94 on Dec 06. It resulted in a $4,702 investment by the insider. Downs Christopher added 4,500 shares at an average price of $1.15 on Nov 19. The insider now owns 146,500 shares following the transaction.
In the three months ended December 30, CNS Pharmaceuticals Inc.’s quick ratio stood at 13.80, while its current ratio was 13.80, showing that the company is able to pay off its debt. Based on annual data, CNSP earned -$14.03 million in gross profit.
While analysts expected CNS Pharmaceuticals Inc. to report -$0.16 quarterly earnings, the actual figure was -$0.1 per share, beating the consensus estimate by 37.50%. The liabilities of CNS Pharmaceuticals Inc. were 1.07 million at the end of its most recent quarter ended December 30, and its total debt was $0.39 million. The value of shareholders’ equity is $40.03 million.
This quick technical analysis looks at CNS Pharmaceuticals Inc.’s (CNSP) price momentum. With a historical volatility rate of 103.07%, the RSI 9-day stood at 67.09% on 22 June.
With respect to its five-day moving average, the current CNS Pharmaceuticals Inc. price is up by +19.91% percent or $0.0543. At present, CNSP shares trade +15.79% above its 20-day simple moving average and -43.95% percent below its 100-day simple moving average. However, the stock is currently trading approximately -15.44% below its SMA50 and -79.56% below its SMA200.
Stochastic coefficient K was 30.59% and Stochastic coefficient D was 22.74%, while ATR was 0.0352. Given the Stochastic reading of 57.36% for the 14-day period, the RSI (14) reading has been calculated as 59.71%. As of today, the MACD Oscillator reading stands at 0.0118.
CNS Pharmaceuticals Inc. downgraded its rating on CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to a Neutral in a note to investors on December 28, 2020. The analysts firm previously had a Buy rating on the stock.CNS Pharmaceuticals Inc. (CNSP) has been rated Buy by analysts. According to 0 brokerage firms, CNSP is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate CNS Pharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $1.00, the current consensus forecast for the stock is $1.00 – $1.00. Based on these forecasts, analysts predict CNS Pharmaceuticals Inc. (CNSP) will achieve an average price target of $1.00.